Napo formed Jaguar to develop and commercialize animal health products. A significant proportion of patients undergoing cancer therapy experience diarrhea. NIAID is part of the National Institutes of Health. In these people, rapid loss of body fluids leads to dehydration and shock. Without treatment, death can occur within hours. Ten members of the Jaguar and Napo team have been together for more than 15 years. Top line results for the study are expected to be available in the second half of 2021. At that point in time, enrollment in the study exceeded 85%. Through Napo, we hold an extensive global patent portfolio. Key members of this team successfully developed Mytesi. Napo is receiving preclinical services from the NIAID to support lechlemer development. Crofelemer was well tolerated at all doses. The infection is often mild or without symptoms, but can sometimes be severe. We are investigating lechlemer for the indication of cholera/general watery diarrhea. Diarrhea predominant irritable bowel syndrome. Crofelemer represents a new tool in gastrointestinal disease management. The FDA may request additional information rather than accept an NDA for filing. We do not believe that our non-prescription products fit within this framework either. On November 6, 2018, the Defendants moved to dismiss the second amended complaint. 8203;Corporate InformationWe were incorporated in the State of Delaware on June 6, 2013. We plan to rely on certain of these issued patents as protection for Canalevia. Similar changes in laws or regulations can occur in other countries. The reason for the volatility in our stock is not well understood and may continue. This is often referred to as a "short squeeze."